Cancer Diagnostics Global Market - Forecast to 2026
The understanding of the pathways of cancer development and their causes has led to the development of novel methodologies, and there is an emerging trend towards precision health in today’s world to enhance cancer diagnosis, treatment, prevention and monitoring by using innovative diagnostic technologies with broader range.
Over the past few years technical advancements has led to the progression in cancer screening and treatment. The rise in number of new cases necessitates for more improvised technologies in diagnosis and monitoring of cancer. Cancer diagnostics are the foundation for the successful cancer prevention, where it provides quantitative measurements, changes at the genetic level thereby finding the underlying mechanism of disease and enabling the oncologist to tailor care at individual level and facilitating the personalized medicine practice.
Due to the side effects of radiation and other image-based diagnosis of cancer, there is a huge opportunity for non-image based techniques such as in-vitro diagnostics comprising tests based on molecular biology and immunology. These tests provide rapid and precise information about cancer and have revolutionized cancer management around the world. Some of the advantages of non-image based diagnostics are, up to 70% of the healthcare decisions are influenced by molecular and immune-based tests further improving the quality of personalized care of the patient, potential improvement in the patient outcome and facilitate early detection of cancer with sensitive assays thereby reducing the cost of healthcare of an individual.
According to IQ4I analysis, the cancer diagnostics global market is expected to reach $10,627.4 million by 2026 growing at a high single digit CAGR from 2019 to 2026. The growth of cancer diagnostic market is driven by the increasing number of cancer associated with the lifestyle, dramatic changes in the demography, advances in the disease genomics, also adoption of nationwide cancer screening programs as a part of national cancer control plans by individual countries (almost 120 countries have included national plans for cervical and breast cancer screening programs respectively) and discovery of new drugs. Cancer diagnostic tests have provided a greater value and are likely to play an escalating role in the future market.
The commercialization of cancer diagnostics techniques depends on economical, clinical and logistic challenges. One among them is the reimbursement system with suitable coding, positive coverage, and assessment of the price of novel diagnostics. With the reimbursement policies, all patients can access all new diagnostic tests on sustained bases thereby reducing the financial pressure. Also, high investment by major players for the production and release of new diagnostics techniques to the market will have a major role in driving the cancer diagnostics market. The restraints of the cancer diagnostics will include lack of skilled professionals, high cost of advanced techniques, product recall due to manufacturing defects and quality issues, stringent and time consumption for getting approvals from the regulatory bodies, lack of reimbursement will also hamper the growth of cancer diagnostic market.
The cancer diagnostics global market is segmented based on technology, sample source, application and end-users. The technology market is further categorized into immunoassays, molecular-based assays and others. The immunoassays global market is further sub-segmented into Immunohistochemistry (IHC), Enzyme Linked Immunosorbent Assay (ELISA) and others comprising of RIA (Radioimmunoassay), CLIA (Chemiluminescence), and FIA (Fluorescence immunoassays), among which, ELISA commanded the largest revenue in 2019, and IHC is expected to grow at a strong double digit CAGR from 2019 to 2026. The molecular-based global market is further sub-segmented into in-situ hybridization, PCR, microarray and sequencing, among which PCR commanded the largest revenue in 2019, the sequencing segment is expected to grow at a strong double digit CAGR from 2019 to 2026. The other technology segment is expected to grow at a mid single digit CAGR from 2019 to 2026.
Based on the source of the sample taken for performing the diagnostic test, the market is segmented into three categories, viz., blood, tissue and others. Among these segment, blood accounted for the largest revenue generation in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The blood-based tests provide accurate results when compare to tissue and other source and its less painful for collection from the individual compare to tissue and other source such as cerebrospinal fluid, bone marrow aspirate sample. Also, blood as a sample source can be used for early diagnosis before the occurrence of symptoms.
The cancer diagnostics by the application are classified into cancer type and cancer care segment. The market based on cancer type is further segmented into lung, breast, colorectal, prostate, ovarian, liver and other cancers. The largest revenue was generated by colorectal cancer in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The cancer care segment is further classified into diagnosis, early screening, companion diagnostics, prognosis and monitoring. Among which, diagnosis accounted for the largest revenue in 2019 whereas, companion diagnostics segment is expected to grow at a strong double digit CAGR from 2019 to 2026.
The cancer diagnostics end-user market is segmented into hospitals, clinical/centralized laboratories, and other end-users such as biopharma, academics and research. Clinical/centralized laboratories segment accounted for the largest revenue in 2019 owing to the access of advanced and novel technologies for the diagnosis and also the availability of skilled professionals with more capital investments as compared with hospitals. Hospitals segment is expected to grow at a high single digit CAGR from 2019 to 2026.
Geographical wise, North America region commanded the largest revenue in 2019, owing to the high demand for early detection, treatment and prevention of cancer with advanced technology due to larger outbreaks of cancer associated with the lifestyle. However, the Asia-Pacific region is expected to grow at a strong double digit CAGR from 2019 to 2026 owing to higher incidence of cancer cases compare to other regions and also increasing awareness programmes on the need for screening and prevention of cancer at early stages.
The cancer diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion and technological innovations.
Some of the key players in cancer diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), Qiagen (Netherlands), Exact Sciences Corporation (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Siemens Healthineers (Germany), and Guardant Health (U.S.).
Over the past few years technical advancements has led to the progression in cancer screening and treatment. The rise in number of new cases necessitates for more improvised technologies in diagnosis and monitoring of cancer. Cancer diagnostics are the foundation for the successful cancer prevention, where it provides quantitative measurements, changes at the genetic level thereby finding the underlying mechanism of disease and enabling the oncologist to tailor care at individual level and facilitating the personalized medicine practice.
Due to the side effects of radiation and other image-based diagnosis of cancer, there is a huge opportunity for non-image based techniques such as in-vitro diagnostics comprising tests based on molecular biology and immunology. These tests provide rapid and precise information about cancer and have revolutionized cancer management around the world. Some of the advantages of non-image based diagnostics are, up to 70% of the healthcare decisions are influenced by molecular and immune-based tests further improving the quality of personalized care of the patient, potential improvement in the patient outcome and facilitate early detection of cancer with sensitive assays thereby reducing the cost of healthcare of an individual.
According to IQ4I analysis, the cancer diagnostics global market is expected to reach $10,627.4 million by 2026 growing at a high single digit CAGR from 2019 to 2026. The growth of cancer diagnostic market is driven by the increasing number of cancer associated with the lifestyle, dramatic changes in the demography, advances in the disease genomics, also adoption of nationwide cancer screening programs as a part of national cancer control plans by individual countries (almost 120 countries have included national plans for cervical and breast cancer screening programs respectively) and discovery of new drugs. Cancer diagnostic tests have provided a greater value and are likely to play an escalating role in the future market.
The commercialization of cancer diagnostics techniques depends on economical, clinical and logistic challenges. One among them is the reimbursement system with suitable coding, positive coverage, and assessment of the price of novel diagnostics. With the reimbursement policies, all patients can access all new diagnostic tests on sustained bases thereby reducing the financial pressure. Also, high investment by major players for the production and release of new diagnostics techniques to the market will have a major role in driving the cancer diagnostics market. The restraints of the cancer diagnostics will include lack of skilled professionals, high cost of advanced techniques, product recall due to manufacturing defects and quality issues, stringent and time consumption for getting approvals from the regulatory bodies, lack of reimbursement will also hamper the growth of cancer diagnostic market.
The cancer diagnostics global market is segmented based on technology, sample source, application and end-users. The technology market is further categorized into immunoassays, molecular-based assays and others. The immunoassays global market is further sub-segmented into Immunohistochemistry (IHC), Enzyme Linked Immunosorbent Assay (ELISA) and others comprising of RIA (Radioimmunoassay), CLIA (Chemiluminescence), and FIA (Fluorescence immunoassays), among which, ELISA commanded the largest revenue in 2019, and IHC is expected to grow at a strong double digit CAGR from 2019 to 2026. The molecular-based global market is further sub-segmented into in-situ hybridization, PCR, microarray and sequencing, among which PCR commanded the largest revenue in 2019, the sequencing segment is expected to grow at a strong double digit CAGR from 2019 to 2026. The other technology segment is expected to grow at a mid single digit CAGR from 2019 to 2026.
Based on the source of the sample taken for performing the diagnostic test, the market is segmented into three categories, viz., blood, tissue and others. Among these segment, blood accounted for the largest revenue generation in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The blood-based tests provide accurate results when compare to tissue and other source and its less painful for collection from the individual compare to tissue and other source such as cerebrospinal fluid, bone marrow aspirate sample. Also, blood as a sample source can be used for early diagnosis before the occurrence of symptoms.
The cancer diagnostics by the application are classified into cancer type and cancer care segment. The market based on cancer type is further segmented into lung, breast, colorectal, prostate, ovarian, liver and other cancers. The largest revenue was generated by colorectal cancer in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The cancer care segment is further classified into diagnosis, early screening, companion diagnostics, prognosis and monitoring. Among which, diagnosis accounted for the largest revenue in 2019 whereas, companion diagnostics segment is expected to grow at a strong double digit CAGR from 2019 to 2026.
The cancer diagnostics end-user market is segmented into hospitals, clinical/centralized laboratories, and other end-users such as biopharma, academics and research. Clinical/centralized laboratories segment accounted for the largest revenue in 2019 owing to the access of advanced and novel technologies for the diagnosis and also the availability of skilled professionals with more capital investments as compared with hospitals. Hospitals segment is expected to grow at a high single digit CAGR from 2019 to 2026.
Geographical wise, North America region commanded the largest revenue in 2019, owing to the high demand for early detection, treatment and prevention of cancer with advanced technology due to larger outbreaks of cancer associated with the lifestyle. However, the Asia-Pacific region is expected to grow at a strong double digit CAGR from 2019 to 2026 owing to higher incidence of cancer cases compare to other regions and also increasing awareness programmes on the need for screening and prevention of cancer at early stages.
The cancer diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion and technological innovations.
Some of the key players in cancer diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), Qiagen (Netherlands), Exact Sciences Corporation (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Siemens Healthineers (Germany), and Guardant Health (U.S.).
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITY
3.3.1.1 Rising incidence of cancer and old age population
3.3.1.2 Increase in technological advancement in cancer diagnostics
3.3.1.3 Increase in healthcare expenditure
3.3.1.4 Infrastructure and investments by government and private companies
3.3.1.5 emerging markets and increasing awareness of various cancers
3.3.1.6 Personalized medicine
3.3.1.7 Mandatory early screening
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High cost of advanced technologies
3.3.2.2 Lack of skilled professionals hampering the growth of cancer diagnostics market
3.3.2.3 Product recall due to manufacturing and quality issues
3.3.2.4 Stringent regulations
3.3.2.5 Lack of reimbursement
3.4 MARKET SHARE ANALYSIS
3.4.1 CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 CHINA
3.5.4 INDIA
3.5.5 JAPAN
3.5.6 AUSTRALIA
3.5.7 SOUTH KOREA
3.6 REIMBURSEMENT SCENARIO
3.7 CLINICAL TRIALS
3.7.1 CTDNA CLINICALTRIALS
3.7.2 CFDNA CLINICALTRIALS
3.7.3 CIRCULATING TUMOR CELLS
3.7.4 COMPANION DIAGNOSTICS
3.7.5 IMMUNOASSAYS
3.8 PORTER’S FIVE FORCE ANALYSIS
3.8.1 THREAT OF NEW ENTRANTS
3.8.2 THREAT OF SUBSTITUTES
3.8.3 COMPETITIVE RIVALRY
3.8.4 BARGAINING POWER OF SUPPLIERS
3.8.5 BARGAINING POWER OF BUYERS
4 CANCER DIAGNOSTICS PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM)
4.1 RESEARCH METHODOLOGY
4.2 FORECAST METHODOLOGY
4.3 NORTH AMERICA CANCER DIAGNOSIS ADDRESSABLE MARKET
4.3.1 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM)
4.3.1.1 Early Screening:
4.3.1.2 U.S. colorectal cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM)
4.3.2 U.S. BREAST CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
4.3.2.1 Early Screening
4.3.2.2 U.S. breast cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM):
4.3.3 U.S. PROSTATE CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
4.3.3.1 Early Screening:
4.3.3.2 U.S. prostate cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM)
4.3.4 U.S. LUNG CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
4.3.4.1 Early Screening:
4.3.4.2 U.S. lung cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (tam):
4.3.5 U.S. OTHER CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.3.6 REST OF N.A. CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.4 EUROPE CANCER DIAGNOSIS ADDRESSABLE MARKET
4.4.1 EUROPE CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.5 APAC CANCER DIAGNOSIS ADDRESSABLE MARKET
4.5.1 APAC CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.6 ROW CANCER DIAGNOSIS ADDRESSABLE MARKET
4.6.1 ROW CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.7 CANCER CARE GLOBAL ADDRESSABLE MARKET
4.7.1 EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKETBY CANCER TYPE AND BY REGION
4.7.2 PROGNOSIS MONITORING GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
4.7.3 COMPANION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
4.7.4 RECURRENCE MONITORING GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
5 CANCER DIANOSTICS GLOBAL MARKET, BY TECHNOLOGY
5.1 INTRODUCTION
5.2 IMMUNOASSAYS
5.2.1 IMMUNOHISTOCHEMISTRY (IHC)
5.2.2 ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA)
5.3.3 OTHER IMMUNOASSAYS
5.4 MOLECULAR BASED ASSAYS
5.4.1 IN-SITU HYBRIDIZATION
5.4.2 POLYMERASE CHAIN REACTION (PCR)
5.4.3 MICROARRAY
5.4.4 SEQUENCING
5.5 OTHERS
6 CANCER DIAGNOSTICS GLOBAL MARKET, BY SAMPLE SOURCE
6.1 INTRODUCTION
6.2 BLOOD
6.3 TISSUE
6.4 OTHERS
7 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER TYPE
7.1 INTRODUCTION
7.2 CANCER TYPES
7.2.1 LUNG CANCER
7.2.2 BREAST CANCER
7.2.3 COLORECTAL CANCER
7.2.4 PROSTATE CANCER
7.2.5 LIVER CANCER
7.2.6 OVARIAN CANCER
7.2.7 OTHERS
8 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER CARE
8.1 INTRODUCTION
8.2 DIAGNOSIS
8.3 EARLY SCREENING
8.4 COMPANION DIAGNOSIS
8.5 PROGNOSIS
8.6 RECURRENCE MONITORING
9 CANCER DIAGNOSTICS GLOBAL MARKET, BY END-USERS
9.1 INTRODUCTION
9.2 HOSPITALS
9.3 CLINICAL/CENTRALIZED LABORATORIES
9.4 OTHERS
10 CANCER DIAGNOSTICS GLOBAL MARKET BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 REST OF NORTH AMERICA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UNITED KINGDOM
10.3.4 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 BRAZIL
10.5.2 REST OF LATIN AMERICA
10.5.3 MIDDLE EAST AND OTHER COUNTRIES
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 APPROVALS
11.3 COLLABORATION
11.4 NEW PRODUCT LAUNCHES
11.5 ACQUSTIONS
11.6 OTHERS
12 MAJOR COMPANIES
12.1 ABBOTT LABORATORIES
12.1.1 OVERVIEW
12.1.2 FINANCIALS
12.1.3 PRODUCT PORTFOLIO
12.1.4 KEY DEVELOPMENTS
12.1.5 BUSINESS STRATEGY
12.1.6 SWOT ANALYSIS
12.2 AGILENT TECHNOLOGIES, INC
12.2.1 OVERVIEW
12.2.2 FINANCIALS
12.2.3 PRODUCT PORTFOLIO
12.2.4 KEY DEVELOPMENTS
12.2.5 BUSINESS STRATEGY
12.2.6 SWOT ANALYSIS
12.3 DANAHER CORPORATION
12.3.1 OVERVIEW
12.3.2 FINANCIALS
12.3.3 PRODUCT PORTFOLIO
12.3.4 KEY DEVELOPMENTS
12.3.5 BUSINESS STRATEGY
12.3.6 SWOT ANALYSIS
12.4 EXACT SCIENCES CORPORATION
12.4.1 OVERVIEW
12.4.2 FINANCIALS
12.4.3 PRODUCT PORTFOLIO
12.4.4 KEY DEVELOPMENTS
12.4.5 BUSINESS STRATEGY
12.4.6 SWOT ANALYSIS
12.5 GUARDANT HEALTH, INC.
12.5.1 OVERVIEW
12.5.2 FINANCIALS
12.5.3 PRODUCT PORTFOLIO
12.5.4 KEY DEVELOPMENTS
12.5.5 BUSINESS STRATEGY
12.5.6 SWOT ANALYSIS
12.6 HOLOGIC, INC.
12.6.1 OVERVIEW
12.6.2 FINANCIALS
12.6.3 PRODUCT PORTFOLIO
12.6.4 KEY DEVELOPMENTS
12.6.5 BUSINESS STRATEGY
12.6.6 SWOT ANALYSIS
12.7 MYRIAD GENETICS, INC.
12.7.1 OVERVIEW
12.7.2 FINANCIALS
12.7.3 PRODUCT PORTFOLIO
12.7.4 KEY DEVELOPMENTS
12.7.5 BUSINESS STRATEGY
12.7.6 SWOT ANALYSIS
12.8 QIAGEN N.V.
12.8.1 OVERVIEW
12.8.2 FINANCIALS
12.8.3 PRODUCT PORTFOLIO
12.8.4 KEY DEVELOPMENTS
12.8.5 BUSINESS STRATEGY
12.8.6 SWOT ANALYSIS
12.9 ROCHE
12.9.1 OVERVIEW
12.9.2 FINANCIALS
12.9.3 PRODUCT PORTFOLIO
12.9.4 KEY DEVELOPMENTS
12.9.5 BUSINESS STRATEGY
12.9.6 SWOT ANALYSIS
12.10 SIEMENS HEALTHINEERS
12.10.1 OVERVIEW
12.10.2 FINANCIALS
12.10.3 PRODUCT PORTFOLIO
12.10.4 KEY DEVELOPMENTS
12.10.5 BUSINESS STRATEGY
12.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITY
3.3.1.1 Rising incidence of cancer and old age population
3.3.1.2 Increase in technological advancement in cancer diagnostics
3.3.1.3 Increase in healthcare expenditure
3.3.1.4 Infrastructure and investments by government and private companies
3.3.1.5 emerging markets and increasing awareness of various cancers
3.3.1.6 Personalized medicine
3.3.1.7 Mandatory early screening
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High cost of advanced technologies
3.3.2.2 Lack of skilled professionals hampering the growth of cancer diagnostics market
3.3.2.3 Product recall due to manufacturing and quality issues
3.3.2.4 Stringent regulations
3.3.2.5 Lack of reimbursement
3.4 MARKET SHARE ANALYSIS
3.4.1 CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 CHINA
3.5.4 INDIA
3.5.5 JAPAN
3.5.6 AUSTRALIA
3.5.7 SOUTH KOREA
3.6 REIMBURSEMENT SCENARIO
3.7 CLINICAL TRIALS
3.7.1 CTDNA CLINICALTRIALS
3.7.2 CFDNA CLINICALTRIALS
3.7.3 CIRCULATING TUMOR CELLS
3.7.4 COMPANION DIAGNOSTICS
3.7.5 IMMUNOASSAYS
3.8 PORTER’S FIVE FORCE ANALYSIS
3.8.1 THREAT OF NEW ENTRANTS
3.8.2 THREAT OF SUBSTITUTES
3.8.3 COMPETITIVE RIVALRY
3.8.4 BARGAINING POWER OF SUPPLIERS
3.8.5 BARGAINING POWER OF BUYERS
4 CANCER DIAGNOSTICS PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM)
4.1 RESEARCH METHODOLOGY
4.2 FORECAST METHODOLOGY
4.3 NORTH AMERICA CANCER DIAGNOSIS ADDRESSABLE MARKET
4.3.1 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM)
4.3.1.1 Early Screening:
4.3.1.2 U.S. colorectal cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM)
4.3.2 U.S. BREAST CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
4.3.2.1 Early Screening
4.3.2.2 U.S. breast cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM):
4.3.3 U.S. PROSTATE CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
4.3.3.1 Early Screening:
4.3.3.2 U.S. prostate cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM)
4.3.4 U.S. LUNG CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM)
4.3.4.1 Early Screening:
4.3.4.2 U.S. lung cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (tam):
4.3.5 U.S. OTHER CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.3.6 REST OF N.A. CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.4 EUROPE CANCER DIAGNOSIS ADDRESSABLE MARKET
4.4.1 EUROPE CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.5 APAC CANCER DIAGNOSIS ADDRESSABLE MARKET
4.5.1 APAC CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.6 ROW CANCER DIAGNOSIS ADDRESSABLE MARKET
4.6.1 ROW CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM)
4.7 CANCER CARE GLOBAL ADDRESSABLE MARKET
4.7.1 EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKETBY CANCER TYPE AND BY REGION
4.7.2 PROGNOSIS MONITORING GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
4.7.3 COMPANION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
4.7.4 RECURRENCE MONITORING GLOBAL TOTAL ADDRESSABLE MARKET BY REGION
5 CANCER DIANOSTICS GLOBAL MARKET, BY TECHNOLOGY
5.1 INTRODUCTION
5.2 IMMUNOASSAYS
5.2.1 IMMUNOHISTOCHEMISTRY (IHC)
5.2.2 ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA)
5.3.3 OTHER IMMUNOASSAYS
5.4 MOLECULAR BASED ASSAYS
5.4.1 IN-SITU HYBRIDIZATION
5.4.2 POLYMERASE CHAIN REACTION (PCR)
5.4.3 MICROARRAY
5.4.4 SEQUENCING
5.5 OTHERS
6 CANCER DIAGNOSTICS GLOBAL MARKET, BY SAMPLE SOURCE
6.1 INTRODUCTION
6.2 BLOOD
6.3 TISSUE
6.4 OTHERS
7 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER TYPE
7.1 INTRODUCTION
7.2 CANCER TYPES
7.2.1 LUNG CANCER
7.2.2 BREAST CANCER
7.2.3 COLORECTAL CANCER
7.2.4 PROSTATE CANCER
7.2.5 LIVER CANCER
7.2.6 OVARIAN CANCER
7.2.7 OTHERS
8 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER CARE
8.1 INTRODUCTION
8.2 DIAGNOSIS
8.3 EARLY SCREENING
8.4 COMPANION DIAGNOSIS
8.5 PROGNOSIS
8.6 RECURRENCE MONITORING
9 CANCER DIAGNOSTICS GLOBAL MARKET, BY END-USERS
9.1 INTRODUCTION
9.2 HOSPITALS
9.3 CLINICAL/CENTRALIZED LABORATORIES
9.4 OTHERS
10 CANCER DIAGNOSTICS GLOBAL MARKET BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 REST OF NORTH AMERICA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UNITED KINGDOM
10.3.4 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 BRAZIL
10.5.2 REST OF LATIN AMERICA
10.5.3 MIDDLE EAST AND OTHER COUNTRIES
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 APPROVALS
11.3 COLLABORATION
11.4 NEW PRODUCT LAUNCHES
11.5 ACQUSTIONS
11.6 OTHERS
12 MAJOR COMPANIES
12.1 ABBOTT LABORATORIES
12.1.1 OVERVIEW
12.1.2 FINANCIALS
12.1.3 PRODUCT PORTFOLIO
12.1.4 KEY DEVELOPMENTS
12.1.5 BUSINESS STRATEGY
12.1.6 SWOT ANALYSIS
12.2 AGILENT TECHNOLOGIES, INC
12.2.1 OVERVIEW
12.2.2 FINANCIALS
12.2.3 PRODUCT PORTFOLIO
12.2.4 KEY DEVELOPMENTS
12.2.5 BUSINESS STRATEGY
12.2.6 SWOT ANALYSIS
12.3 DANAHER CORPORATION
12.3.1 OVERVIEW
12.3.2 FINANCIALS
12.3.3 PRODUCT PORTFOLIO
12.3.4 KEY DEVELOPMENTS
12.3.5 BUSINESS STRATEGY
12.3.6 SWOT ANALYSIS
12.4 EXACT SCIENCES CORPORATION
12.4.1 OVERVIEW
12.4.2 FINANCIALS
12.4.3 PRODUCT PORTFOLIO
12.4.4 KEY DEVELOPMENTS
12.4.5 BUSINESS STRATEGY
12.4.6 SWOT ANALYSIS
12.5 GUARDANT HEALTH, INC.
12.5.1 OVERVIEW
12.5.2 FINANCIALS
12.5.3 PRODUCT PORTFOLIO
12.5.4 KEY DEVELOPMENTS
12.5.5 BUSINESS STRATEGY
12.5.6 SWOT ANALYSIS
12.6 HOLOGIC, INC.
12.6.1 OVERVIEW
12.6.2 FINANCIALS
12.6.3 PRODUCT PORTFOLIO
12.6.4 KEY DEVELOPMENTS
12.6.5 BUSINESS STRATEGY
12.6.6 SWOT ANALYSIS
12.7 MYRIAD GENETICS, INC.
12.7.1 OVERVIEW
12.7.2 FINANCIALS
12.7.3 PRODUCT PORTFOLIO
12.7.4 KEY DEVELOPMENTS
12.7.5 BUSINESS STRATEGY
12.7.6 SWOT ANALYSIS
12.8 QIAGEN N.V.
12.8.1 OVERVIEW
12.8.2 FINANCIALS
12.8.3 PRODUCT PORTFOLIO
12.8.4 KEY DEVELOPMENTS
12.8.5 BUSINESS STRATEGY
12.8.6 SWOT ANALYSIS
12.9 ROCHE
12.9.1 OVERVIEW
12.9.2 FINANCIALS
12.9.3 PRODUCT PORTFOLIO
12.9.4 KEY DEVELOPMENTS
12.9.5 BUSINESS STRATEGY
12.9.6 SWOT ANALYSIS
12.10 SIEMENS HEALTHINEERS
12.10.1 OVERVIEW
12.10.2 FINANCIALS
12.10.3 PRODUCT PORTFOLIO
12.10.4 KEY DEVELOPMENTS
12.10.5 BUSINESS STRATEGY
12.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 CANCER DIANGOSTICS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 2 EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKET, BY CANCER TYPE VS REGION (2019) ($MN)
TABLE 3 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 4 IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 5 IMMUNOASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 6 IMMUNOHISTOCHEMISTRY (IHC) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 7 ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 8 OTHER IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 9 MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 10 MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 11 IN-SITU HYBRIDIZATION (ISH) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 12 POLYMERASE CHAIN REACTION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 13 MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 14 SEQUENCING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 15 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 16 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 17 BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 18 TISSUE SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 19 OTHER SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 20 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 21 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 22 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 23 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 24 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 25 LIVER CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 26 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 27 OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 28 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 29 DIAGNOSIS GLOBAL MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 30 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 31 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 32 PROGNOSIS MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 33 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 34 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS (2018-2026) ($MN)
TABLE 35 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 36 CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 37 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 38 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 39 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 40 NORTH AMERICA IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 41 NORTH AMERICA MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 42 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 43 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 44 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 45 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 46 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 47 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 48 EUROPE IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 49 EUROPE MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 50 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 51 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 52 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 53 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 54 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 55 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 56 ASIA-PACIFIC IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 57 ASIA-PACIFIC MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 58 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 59 ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 60 ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 61 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 62 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 63 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 64 REST OF THE WORLD IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 65 REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 66 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 67 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 68 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 69 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 70 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 71 APPROVALS (2018-2020)
TABLE 72 COLLABORATIONS (2018-2020)
TABLE 73 NEW PRODUCT LAUNCH (2018-2020)
TABLE 74 ACQUISITIONS (2016-2018)
TABLE 75 OTHERS (2018-2020)
TABLE 76 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 77 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
TABLE 78 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
TABLE 79 AGILENT TECHNOLOGIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 80 AGILENT TECHNOLOGIES, INC: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
TABLE 81 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 82 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 83 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 84 EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 85 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY SEGMENT (2017-2019) ($MN)
TABLE 86 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
TABLE 87 GUARDANT HEALTH, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 88 GUARDANT HEALTH, INC: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 89 GUARDANT HEALTH, INC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 90 HOLOGIC, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 91 HOLOGIC, INC.: TOTAL REVENUE, BY PRODUCT SEGMENT, (2017-2019) ($MN)
TABLE 92 HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 93 MYRIAD GENETICS, INC : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q2) ($MN)
TABLE 94 MYRIAD GENETICS: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q2) ($MN)
TABLE 95 MYRIAD GENETICS:DIAGNOSTICS AND OTHERS BY PRODUCT SEGMENT, (2017-2019) (Q2) ($MN)
TABLE 96 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 97 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 98 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 99 ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 100 ROCHE: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 101 ROCHE: TOTAL REVENUE, BY DIAGNOSTICS SUB-SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 102 ROCHE: TOTAL DIAGNOSTIC REVENUE, BY REGIONS, (2017-2019) (Q3) ($MN)
TABLE 103 SIEMENS HEALTHINEERS : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 104 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY SEGMENT (2017-2019) ($MN)
TABLE 105 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
TABLE 1 CANCER DIANGOSTICS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 2 EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKET, BY CANCER TYPE VS REGION (2019) ($MN)
TABLE 3 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 4 IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 5 IMMUNOASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 6 IMMUNOHISTOCHEMISTRY (IHC) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 7 ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 8 OTHER IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 9 MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 10 MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 11 IN-SITU HYBRIDIZATION (ISH) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 12 POLYMERASE CHAIN REACTION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 13 MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 14 SEQUENCING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 15 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 16 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 17 BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 18 TISSUE SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 19 OTHER SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 20 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 21 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 22 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 23 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 24 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 25 LIVER CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 26 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 27 OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 28 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 29 DIAGNOSIS GLOBAL MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 30 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 31 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 32 PROGNOSIS MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 33 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 34 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS (2018-2026) ($MN)
TABLE 35 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 36 CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 37 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 38 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 39 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 40 NORTH AMERICA IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 41 NORTH AMERICA MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 42 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 43 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 44 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 45 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 46 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 47 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 48 EUROPE IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 49 EUROPE MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 50 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 51 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 52 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 53 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 54 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 55 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 56 ASIA-PACIFIC IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 57 ASIA-PACIFIC MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 58 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 59 ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 60 ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 61 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 62 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 63 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 64 REST OF THE WORLD IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 65 REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 66 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN)
TABLE 67 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 68 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 69 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN)
TABLE 70 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 71 APPROVALS (2018-2020)
TABLE 72 COLLABORATIONS (2018-2020)
TABLE 73 NEW PRODUCT LAUNCH (2018-2020)
TABLE 74 ACQUISITIONS (2016-2018)
TABLE 75 OTHERS (2018-2020)
TABLE 76 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 77 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
TABLE 78 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
TABLE 79 AGILENT TECHNOLOGIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 80 AGILENT TECHNOLOGIES, INC: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
TABLE 81 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 82 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 83 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 84 EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 85 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY SEGMENT (2017-2019) ($MN)
TABLE 86 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
TABLE 87 GUARDANT HEALTH, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 88 GUARDANT HEALTH, INC: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 89 GUARDANT HEALTH, INC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 90 HOLOGIC, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 91 HOLOGIC, INC.: TOTAL REVENUE, BY PRODUCT SEGMENT, (2017-2019) ($MN)
TABLE 92 HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 93 MYRIAD GENETICS, INC : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q2) ($MN)
TABLE 94 MYRIAD GENETICS: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q2) ($MN)
TABLE 95 MYRIAD GENETICS:DIAGNOSTICS AND OTHERS BY PRODUCT SEGMENT, (2017-2019) (Q2) ($MN)
TABLE 96 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 97 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 98 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 99 ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 100 ROCHE: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 101 ROCHE: TOTAL REVENUE, BY DIAGNOSTICS SUB-SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 102 ROCHE: TOTAL DIAGNOSTIC REVENUE, BY REGIONS, (2017-2019) (Q3) ($MN)
TABLE 103 SIEMENS HEALTHINEERS : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 104 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY SEGMENT (2017-2019) ($MN)
TABLE 105 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
LIST OF FIGURES
FIGURE 1 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: CANCER DIAGNOSTICS GLOBAL MARKET
FIGURE 3 CANCER DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 CANCER DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 CANCER DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 CANCER DIAGNOSTICS GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019) (%)
FIGURE 9 CANCER DIAGNOTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 10 U.S. COLORECTAL CANCER EARLY SCREENING PENETRATION AND TOTAL ADDRESSABLE MARKET (%) ($ MN)
FIGURE 11 U.S. COLORECTAL CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TAM ($MN)
FIGURE 12 U.S. COLORECTAL CANCER EARLY SCREENING MARKET SHARE, BY PLAYERS (%)
FIGURE 13 U.S. BREAST CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
FIGURE 14 U.S. BREAST CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 15 U.S. PROSTATE CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
FIGURE 16 U.S. PROSTATE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 17 U.S. LUNG CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
FIGURE 18 U.S. LUNG CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 19 U.S. OTHER CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 20 REST OF N.A. CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 21 EUROPE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 22 APAC CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 23 ROW CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 24 COLORECTAL CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 25 PROSTATE CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 26 BREAST CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 27 LUNG CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 28 PROGNOSIS MONITORING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 29 COMPANION DIAGNOSTICS GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 30 RECURRENCE MONITORING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 31 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 32 IMMUNOASSAY GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 33 MOLECULAR BASED ASSAYS GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 34 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 35 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET SHARE, BY CANCER TYPE (2019 VS 2026) (%)
FIGURE 36 GLOBAL CANCER PREVALENCE AND INCIDENCE RATE BY TYPE (2019) (%)
FIGURE 37 CANCER DIAGNOSTICS APPLICAION GLOBAL MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 38 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USERS (2019 VS 2026) (%)
FIGURE 39 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 40 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, MARKET REVENUE BY COUNTRY (2019) (%) ($MN)
FIGURE 41 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 42 NORTH AMERICA IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 43 NORTH AMERICA MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 44 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 45 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER TYPE (2019 VS 2026) (%)
FIGURE 46 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 47 NORTH AMERICA CANCER DIAGNOSTICS L MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 48 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 49 U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 50 U.S. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 51 U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 52 REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 53 REST OF NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 54 REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 55 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 56 EUROPE IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 57 EUROPE MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 58 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 59 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 60 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 61 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 62 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 63 GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 64 GERMANY CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 65 GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 66 FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 67 FRANCE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 68 FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 69 U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 70 U.K. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 71 U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 72 REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 73 REST OF EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 74 REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 75 APAC CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 76 APAC IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 77 APAC MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 78 APAC CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 79 APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 80 APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 81 APAC CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 82 APAC CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 83 JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 84 JAPAN CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 85 JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 86 CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 87 CHINA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 88 CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 89 INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 90 INDIA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 91 INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 92 REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 93 REST OF APACCANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 94 REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 95 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 96 REST OF THE WORLD IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 97 REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 98 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 99 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 100 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 101 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 102 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 103 BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 104 BRAZIL CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 105 BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 106 REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 107 REST OF LATIN AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 108 REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 109 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 110 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 111 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 112 KEY GROWTH STRATEGIES, (2018 – 2020)
FIGURE 113 SWOT: ABBOTT LABORATORIES
FIGURE 114 SWOT: AGILENT TECHNOLOGIES
FIGURE 115 SWOT: DANAHER CORPORATION
FIGURE 116 SWOT: EXACT SCIENCES
FIGURE 117 SWOT: GUARDANT HEALTH
FIGURE 118 SWOT: HOLOGIC INC.
FIGURE 119 SWOT: MYRIAD GENETICS
FIGURE 120 SWOT: QIAGEN N.V.
FIGURE 121 SWOT: ROCHE
FIGURE 122 SWOT: SIEMENS HEALTHINEERS
FIGURE 1 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: CANCER DIAGNOSTICS GLOBAL MARKET
FIGURE 3 CANCER DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 CANCER DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 CANCER DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 CANCER DIAGNOSTICS GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019) (%)
FIGURE 9 CANCER DIAGNOTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 10 U.S. COLORECTAL CANCER EARLY SCREENING PENETRATION AND TOTAL ADDRESSABLE MARKET (%) ($ MN)
FIGURE 11 U.S. COLORECTAL CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TAM ($MN)
FIGURE 12 U.S. COLORECTAL CANCER EARLY SCREENING MARKET SHARE, BY PLAYERS (%)
FIGURE 13 U.S. BREAST CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
FIGURE 14 U.S. BREAST CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 15 U.S. PROSTATE CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
FIGURE 16 U.S. PROSTATE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 17 U.S. LUNG CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN)
FIGURE 18 U.S. LUNG CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 19 U.S. OTHER CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 20 REST OF N.A. CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 21 EUROPE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 22 APAC CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 23 ROW CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN)
FIGURE 24 COLORECTAL CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 25 PROSTATE CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 26 BREAST CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 27 LUNG CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 28 PROGNOSIS MONITORING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 29 COMPANION DIAGNOSTICS GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 30 RECURRENCE MONITORING GLOBAL TAM, BY REGION, 2019 ($MN)
FIGURE 31 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 32 IMMUNOASSAY GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 33 MOLECULAR BASED ASSAYS GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 34 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 35 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET SHARE, BY CANCER TYPE (2019 VS 2026) (%)
FIGURE 36 GLOBAL CANCER PREVALENCE AND INCIDENCE RATE BY TYPE (2019) (%)
FIGURE 37 CANCER DIAGNOSTICS APPLICAION GLOBAL MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 38 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USERS (2019 VS 2026) (%)
FIGURE 39 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 40 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, MARKET REVENUE BY COUNTRY (2019) (%) ($MN)
FIGURE 41 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 42 NORTH AMERICA IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 43 NORTH AMERICA MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 44 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 45 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER TYPE (2019 VS 2026) (%)
FIGURE 46 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 47 NORTH AMERICA CANCER DIAGNOSTICS L MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 48 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 49 U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 50 U.S. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 51 U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 52 REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 53 REST OF NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 54 REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 55 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 56 EUROPE IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 57 EUROPE MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 58 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 59 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 60 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 61 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 62 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 63 GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 64 GERMANY CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 65 GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 66 FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 67 FRANCE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 68 FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 69 U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 70 U.K. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 71 U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 72 REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 73 REST OF EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 74 REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 75 APAC CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 76 APAC IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 77 APAC MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 78 APAC CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 79 APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 80 APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 81 APAC CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 82 APAC CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 83 JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 84 JAPAN CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 85 JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 86 CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 87 CHINA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 88 CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 89 INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 90 INDIA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 91 INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 92 REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 93 REST OF APACCANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 94 REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 95 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 96 REST OF THE WORLD IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 97 REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%)
FIGURE 98 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%)
FIGURE 99 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 100 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 101 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 102 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
FIGURE 103 BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 104 BRAZIL CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 105 BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 106 REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 107 REST OF LATIN AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 108 REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 109 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN)
FIGURE 110 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN)
FIGURE 111 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN)
FIGURE 112 KEY GROWTH STRATEGIES, (2018 – 2020)
FIGURE 113 SWOT: ABBOTT LABORATORIES
FIGURE 114 SWOT: AGILENT TECHNOLOGIES
FIGURE 115 SWOT: DANAHER CORPORATION
FIGURE 116 SWOT: EXACT SCIENCES
FIGURE 117 SWOT: GUARDANT HEALTH
FIGURE 118 SWOT: HOLOGIC INC.
FIGURE 119 SWOT: MYRIAD GENETICS
FIGURE 120 SWOT: QIAGEN N.V.
FIGURE 121 SWOT: ROCHE
FIGURE 122 SWOT: SIEMENS HEALTHINEERS
